Advertisement

Topics

BMS Boosts Oncology Pipeline With IFM Therapeutics Acquisition

13:00 EDT 7 Aug 2017 | Drug Discovery Development

Under the terms of the agreement, Bristol-Myers Squibb will pay $300 million upon closing of the transaction.
Contributed Author: 
BMS
Topics: 

Original Article: BMS Boosts Oncology Pipeline With IFM Therapeutics Acquisition

NEXT ARTICLE

More From BioPortfolio on "BMS Boosts Oncology Pipeline With IFM Therapeutics Acquisition"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...